OM:SOBIBiotechs
What’s Behind Swedish Orphan Biovitrum (OM:SOBI) Shares Climbing Today?
Swedish Orphan Biovitrum (OM:SOBI) has moved into rare oncology with a new agreement with Innate Pharma that supports the TELLOMAK-3 Phase 3 trial of lacutamab in cutaneous T cell lymphoma.
See our latest analysis for Swedish Orphan Biovitrum.
The Innate Pharma agreement comes as Swedish Orphan Biovitrum trades at SEK457.8, with a year to date share price return of 38.56% and a 1 year total shareholder return of 62.92%. This suggests momentum has been building over the past year.
If this move...